🎙️ Innotion Conversation: Scaling Personalized Healthcare — Insights from Luis Valente of ILOF

In this episode of Innotion Conversation, host Ricardo Pascual speaks with Luis Valente, CEO of ILOF, a groundbreaking deep-tech health company revolutionizing personalized medicine through data-driven patient identification for clinical trials.

They explore:

• The journey of launching and scaling a deep-tech startup in the healthcare sector.
• How ILOF leverages big data to pinpoint the right patients for clinical studies, making personalized medicine accessible on a large scale.
• Luis’s advice on the early-stage challenges of building a deep-tech company, from team formation to market entry.
• The critical importance of creating goodwill and fostering strong internal teams for startup success.
• Differences in market dynamics and fundraising strategies between the US and Europe.
• Practical insights on raising capital and deciding when and why to expand into the US market.
• The future possibilities and current limitations of personalized medicine.

Luis shares candid reflections on entrepreneurship, innovation, and the complexities of scaling solutions that can dramatically improve patient outcomes globally.

Brought to you by Startup Summit 2025 — Europe’s leading startup and investor summit, happening September 18–19, 2025, in Lisbon.

🎟️ Learn more and secure your spot at www.startupsummit.io

🕒 Chapters 00:00 — Introduction and Background 01:02 — Falling in Love with the Problem 03:14 — Starting a Deep Tech Startup 04:33 — Considerations for Building a Company in the US 07:26 — Creating Goodwill and Building a Team 10:11 — Challenges in the Early Stages 12:01 — Recognition and Achievements 13:47 — The Process and Impact of ILOF's Solution 15:35 — The Future of Personalized Medicine 20:35 — US Market vs. European Market 24:10 — Raising Capital in the US 26:17 — Building a Company in the US: When and Why 27:07 — Conclusion

💡 Key Takeaways

• Deep-tech startups must thoroughly understand the problem they're solving.
• Big data analytics can significantly streamline patient selection in clinical trials.
• Goodwill, strong team culture, and clear mission alignment are crucial to early-stage startup resilience.
• The US market offers distinct opportunities and challenges compared to Europe, particularly regarding capital access and scale.
• The future of medicine is personalized, driven by data-driven insights and innovations like those from ILOF.